IONS•benzinga•
Drugmaker Ionis Pharmaceuticals Garners Analyst Praise For 'Pipeline Depth'
Summary
HC Wainwright initiates Ionis with Buy rating and $45 target, citing strong pipeline, solid revenue, and key clinical milestones ahead.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on April 7, 2025 by benzinga